Chinese Securities Company Praises MEDIPOST as a “Company with Most Profitable Stem Cell Drug”2017/04/26STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Next-Generation Stem Cell Culturing Technology2017/01/10STEM CELL THERAPEUTIC
MEDIPOST Signs MOU with Canadian Public-Private Consortium Funded by the Government of Canada2016/12/01STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in China for Its Brain Disease Treatment Technology that Uses Stem Cells2016/11/30STEM CELL THERAPEUTIC
MEDIPOST Completes Phase 1 and 2 Clinical Trials with its Lung Disease Treatment Drug ‘PNEUMOSTEM’ in US2016/06/30STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in US for its Alzheimer’s Disease Treatment Drug2016/06/08STEM CELL THERAPEUTIC
MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease2016/05/03STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in China for its Alzheimer’s Disease Treatment Substance2016/04/06STEM CELL THERAPEUTIC
MEDIPOST Obtains Patent in Canada for its ‘PNEUMOSTEM’ Used to Treat Lung Diseases2016/03/10STEM CELL THERAPEUTIC
MEDIPOST Obtains Stem Cell Therapy Patent in Japan for Treating Alzheimer’s Disease2016/01/13STEM CELL THERAPEUTIC
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01
Medipost to launch a CDMO business for cell and gene therapy products in Korea based on 20 years of research and production knowledge2022/10/17
Medipost enters North American market by acquiring OmniaBio, a CDMO company with cell and gene therapy products2022/05/31
